Skip to content

To evaluate safety of a test product for skin irritation

Evaluation of Skin Safety of a test product Minoxidil 10%w/v and Finasteride 0.1%w/v Topical Solution for Primary Skin Irritation Using Skin Irritation Test (Patch Test in Humans) IS 4011:2018 Guidelines.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/06/043046
Enrollment
52
Registered
2022-06-06
Start date
Unknown
Completion date
Unknown
Last updated
2023-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: Minoxidil 10%w/v and Finasteride 0.1%w/v Topical Solution.: Filter papers dipped in test product (to contain approximately 0.04ml solution) will be filled in wells of patch chambers and

Sponsors

Cipla Ltd
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Voluntary men and women between 18 and 60 years. 2.Photo type III to V. Having apparently healthy skin on test area. 3.For whom the Investigator considers that the compliance will be correct. 4. Cooperating, informed of the need and duration of the examinations, and ready to comply with protocol procedures. 5.Having signed a Consent Form. 6. Willingness to avoid intense UV exposure on test site (sun or artificial UV), during the course of the study. 7. Willingness to avoid water contact (i.e.: swimming) or activity which cause sweating (i.e.: exercise, saunaâ?¦), during the course of the study. 8 Should be able to read and write (in English, Hindi or local language). 9. Having valid proof of identity and age.

Exclusion criteria

Exclusion criteria: 1. Pregnancy (by history) and lactating women. 2. Scars, excessive terminal hair or tattoo on the studied area. 3. Dermatological infection/pathology on the level of studied area. 4.Hypersensitivity, allergy antecedent (to any cosmetic product, raw material, hair dye). 5.Any clinically significant systemic or cutaneous disease, which may interfere with study procedures. 6. Chronic illness which may influence the outcome of the study. 7. Participants on any medical treatment either systemic or topical which may interfere with the performance of the study (presently or in the past 1 month). 8. Participant in an exclusion period or participating in another food, cosmetic or therapeutic trial

Design outcomes

Primary

MeasureTime frame
Evaluation of skin irritation reactions (erythema, oedema, dryness, scaling wrinkling), using Draize scale.Timepoint: Induction Phase: - Patch application on Visit V1, V3, V5, V7, V9, V11, V13, V15 and V17. - Patch removal on Visit 2 (V2, V4, V6, V8, V10, V12, V14, V16 and V18). - Scoring on Visit 3 (V3, V5, V7, V9, V11, V13, V15, V17, V19) Rest Phase: 10 â?? 14 days Challenge Phase: Patch application will be on naïve sites on the arm/back on V20; patch will be removed at V21 (24 hours). Scoring on V22 (48 hours), V23 (72 hours). V24 (96 hours).

Secondary

MeasureTime frame
NoneTimepoint: None

Countries

India

Contacts

Public ContactMrs Trupti Chitre

Cipla Ltd.

trupti.chitre@cipla.com9819596674

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026